Literature DB >> 16984809

Selective neuronal degeneration in Huntington's disease.

Catherine M Cowan1, Lynn A Raymond.   

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder that generally begins in middle age with abnormalities of movement, cognition, personality, and mood. Neuronal loss is most marked among the medium-sized projection neurons of the dorsal striatum. HD is an autosomal dominant genetic disorder caused by a CAG expansion in exon 1 of the HD gene, encoding an expanded polyglutamine (polyQ) tract near the N-terminus of the protein huntingtin. Despite identification of the gene mutation more than a decade ago, the normal function of this ubiquitously expressed protein is still under investigation and the mechanisms underlying selective neurodegeneration in HD remain poorly understood. Detailed postmortem analyses of brains of HD patients have provided important clues, and HD transgenic and knock-in mouse models have facilitated investigations into potential pathogenic mechanisms. Subcellular fractionation and immunolocalization studies suggest a role for huntingtin in organelle transport, protein trafficking, and regulation of energy metabolism. Consistent with this, evidence from vertebrate and invertebrate models of HD indicates that expression of the polyQ-expanded form of huntingtin results in early impairment of axonal transport and mitochondrial function. As well, alteration in activity of the N-methyl-d-aspartate (NMDA) type glutamate receptor, which has been implicated as a main mediator of excitotoxic neuronal death, especially in the striatum, is an early effect of mutant huntingtin. Proteolysis and nuclear localization of huntingtin also occur relatively early, while formation of ubiquitinated aggregates of huntingtin and transcriptional dysregulation occur as late effects of the gene mutation. Although each of these processes may contribute to neuronal loss in HD, here we review the data to support a strong role for NMDA receptor (NMDAR)-mediated excitotoxicity and mitochondrial dysfunction in conferring selective neuronal vulnerability in HD.

Entities:  

Mesh:

Year:  2006        PMID: 16984809     DOI: 10.1016/S0070-2153(06)75002-5

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  45 in total

Review 1.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 3.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

4.  Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.

Authors:  Shamayra Smail; Dalbir Bahga; Brittnee McDole; Kathleen Guthrie
Journal:  Chem Senses       Date:  2016-01-18       Impact factor: 3.160

5.  Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity.

Authors:  Srinivasa Subramaniam; Katherine M Sixt; Roxanne Barrow; Solomon H Snyder
Journal:  Science       Date:  2009-06-05       Impact factor: 47.728

6.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

Review 7.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

8.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

9.  Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells.

Authors:  Xue-Jun Li; Xiaoqing Zhang; M Austin Johnson; Zhi-Bo Wang; Timothy Lavaute; Su-Chun Zhang
Journal:  Development       Date:  2009-12       Impact factor: 6.868

10.  Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection.

Authors:  Ivorlyne P Greene; Eun-Young Lee; Natalie Prow; Brownhilda Ngwang; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.